Mayo Clinic developed an AI that analyzes routine pathology slides to classify meningiomas and predict recurrence risk, reducing dependency on advanced genetic testing.
Key Details
- 1Study published in The Lancet Digital Health by Mayo Clinic researchers.
- 2AI models analyze standard H&E slides to classify meningiomas and predict recurrence.
- 3Approach relies on images already used in clinical care, not on expensive genetic tests.
- 4Dataset included tissue samples, images, and clinical data from 672 patients.
- 5AI predictions remained valuable beyond traditional clinical factors like tumor grade or patient age.
- 6Further prospective studies are needed before routine clinical adoption.
Why It Matters
This work shows how imaging AI can extend the power of pathology slides, making advanced tumor insights more universally accessible even where genetic testing isn't available. It holds promise for improved, personalized cancer care using existing imaging workflows.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.